(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 April 2019 (04.04.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/067540 A1

(51) International Patent Classification:
A61F 9/007 (2006.01) *A61M 5/32* (2006.01)
A61K 39/395 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:
PCT/US2018/052855

(22) International Filing Date:
26 September 2018 (26.09.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/564,095	27 September 2017 (27.09.2017)	US
62/574,657	19 October 2017 (19.10.2017)	US
62/579,682	31 October 2017 (31.10.2017)	US
62/632,812	20 February 2018 (20.02.2018)	US

(71) Applicants: **REGENXBIO INC.** [US/US]; 9600 Blackwell Road, Suite 210, Rockville, MD 20850 (US). **THE JOHNS HOPKINS UNIVERSITY** [US/US]; 3400 N. Charles Street, Baltimore, MD 21218 (US).

(72) Inventors: **YOO, Stephen**; 5521 Southwick Street, Bethesda, MD 20817 (US). **REINHARDT, Rickey, Robert**; 108 Apple Grove Road, Silver Spring, MD 20904 (US). **VAN EVEREN, Sherri**; 823 Paulson Circle, Menlo Park, CA 94025 (US). **KOZARSKY, Karen, Fran**; 56 E Levering Mill Road, Bala Cynwyd, PA 19004 (US). **SIMPSON, Curran, Matthew**; 2149 Thurston Road, Frederick, MD 21704 (US). **WU, Zhuchun**; 14716 Soft Wind Drive, North Potomac, MD 20878 (US). **CAMPOCHIARO, Peter, Anthony**; 920 West Lake Avenue, Baltimore, MD 21210 (US). **SHEN, Jikui**; 2017 Paulett Road, Apt 102, Dundalk, MD 21222 (US). **DING, Kun**; 2834 North Calvent Street, Apt 2R, Baltimore, MD 21218 (US).

(74) Agent: **MARTINEK, Sebastian** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB




FIGURE 23

(57) Abstract: Compositions and methods are described for the delivery of a fully human post- translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, *e.g.*, a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration ("nAMD"), also known as "wet" age-related macular degeneration ("WAMD"), age-related macular degeneration ("AMD"), and diabetic retinopathy.

WO 2019/067540 A1

[Continued on next page]

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*